Rasio utang jangka dawa marang modal exicuretx.com (XCUR)

Exicure, Inc. (XCUR) innovations in spherical nucleic acids for cancer therapy define its credit potential. The long-term debt-to-equity coverage ratio demonstrates pricing resilience, with the current mark equal to 0.00. Strict patent barriers and FDA oversight, along with the implementation of laboratory robotics for automated molecule screening and predictive data analysis, strengthen the financial foundation.

The development of SNA gene therapy requires significant capital expenditures for long-term research. This metric is calculated as the ratio of liabilities with a maturity of over one year to total equity. It determines the extent of the company's dependence on external borrowing to finance expansion. An increase in this ratio signals risks of destabilization as borrowing costs rise. By analyzing the ratio of long-term liabilities to equity, an investor assesses the financial stability of Exicure, Inc. (XCUR).